CLAIMS

1. A compound of formula (I):

$$I$$

$$HN^{Ar_1}$$

$$N$$

$$R^2$$

$$R_1$$

$$R_1$$

$$R_4$$

$$I$$

or a pharmaceutically acceptable salt thereof, wherein:

R¹ and R² are each independently R, halogen, CN, NO₂, or TR, or R¹ and R² taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from N, O, or S;


T is an optionally substituted C_1 - C_4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or SO₂;

Ar¹ is an optionally substituted ring selected from: an aryl group selected from a 5-6 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3-8-membered saturated or partially unsaturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10-membered saturated or partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar¹ is optionally substituted at one or more carbon atoms with 0-5 occurrences of –Q-R⁵, and at one or more substitutable nitrogen atoms with –R⁶ and each occurrence of R⁶ is independently R¹, -COR¹, -CO₂(C₁-₆ aliphatic), -CON(R¹)₂, -SO₂N(R²)₂, or -SO₂R¹;

R³ and R⁴ are each independently Z-R⁷, or R³ and R⁴ are taken together to form an optionally substituted saturated, partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur wherein said ring is optionally substituted with 0-5 independent occurrences of Y-R⁸;

- each occurrence of Q, Z, and Y is independently a bond or an optionally substituted C₁-C₆ alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO₂, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO₂, NRCONR, SO, SO₂, NRSO₂, SO₂NR, NRSO₂NR, O, S, or NR;
- each occurrence of R^5 , R^7 and R^8 is independently R', halogen, NO₂, CN, OR', SR', N(R')₂, NR'C(O)R', NR'C(O)N(R')₂, NR'CO₂R', C(O)R', CO₂R', OC(O)R', C(O)N(R')₂, OC(O)N(R')₂, SOR', SO₂R', SO₂N(R')₂, NR'SO₂R', NR'SO₂N(R')₂, PO(OR')₂, C(O)C(O)R', or C(O)CH₂C(O)R'; and
- each occurrence of R is independently hydrogen or an optionally substituted C₁₋₆ aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from C₁₋₈ aliphatic, C₆₋₁₀ aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein two occurrences of R taken together, R and R' taken together, or two occurrences of R' taken together, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; provided that:
 - i) R³ and R⁴ are not simultaneously hydrogen; and
 - ii) when R^3 and R^4 are both methyl, or R^3 is methyl and R^4 is $(CH_2)_2OH$, then Ar^1 is not 3, 4, 5-trimethoxyphenyl.
- 2. The compound of claim 1, wherein Ar¹ are optionally substituted rings selected from:
 - (a) a phenyl, indanyl, or naphthyl ring;
- (b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
 - (c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.
- 3. The compound of claim 1, wherein Ar¹ are optionally substituted rings selected from:
 - (a) a phenyl ring;
 - (b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

- (c) a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.
- 4. The compound of claim 1, wherein Ar¹ is selected from any one of a-bb:



wherein x is 0-5.

- 5. The compound of claim 1, wherein Ar¹ is optionally substituted phenyl, pyrimidinyl, or pyridyl.
- 6. The compound of claim 1, wherein Ar^1 is phenyl and is substituted with two (x = 2) or three (x = 3) occurrences of $Q-R^5$ and Ar^1 is one of the following structures:

$$QR^5$$
 QR^5 QR^5 QR^5 QR^5

wherein each occurrence of QR⁵ is independently CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂.

7. The compound of claim 1, wherein Q is independently a bond or is an optionally substituted C_1 - C_4 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO₂, CONR, OCONR, NRCO, NRCO₂, NRSO₂, SO₂NR, O, S, or

NR; and each occurrence of R^5 is independently selected from R', halogen, NO₂, CN, OR', SR', N(R')₂, NR'C(O)R', NR'C(O)N(R')₂, NR'CO₂R', C(O)R', CO₂R', OC(O)R', C(O)N(R')₂, OC(O)N(R')₂, SOR', SO₂R', SO₂N(R')₂, NR'SO₂R', NR'SO₂N(R')₂, PO(OR')₂, C(O)C(O)R', or C(O)CH₂C(O)R', and x is 0, 1, 2, or 3.


- 8. The compound of claim 1, wherein Q-R⁵ substituents on Ar¹ are CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂, or two adjacent occurrences of Q-R⁵, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.
- 9. The compound of claim 1, wherein Q-R⁵ substituents on Ar¹ are fluoro, iodo, chloro, bromo, COCH₃, CO₂CH₃, C₁₋₄alkyl, NH₂, CH₂NH₂, NHMe, CH₂NHMe, N(Me)₂, CH₂N(Me)₂, N(Et)₂, CH₂N(Et)₂, NH(phenyl), CO(C₁₋₄alkyl), CH₂CO(C₁₋₄alkyl), NHCO(C₁₋₄alkyl), CH₂NHCO(C₁₋₄alkyl), CN, CH₂CN, OH, C₁₋₄alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF₃, SO₂NH₂, SO₂NHMe, optionally substituted SO₂(phenyl), SO₂(C₁₋₄alkyl), CONH₂, CH₂PO(OR')₂, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- 10. The compound of claim 1, wherein R^1 and R^2 groups of formula I are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S.
- 11. The compound of claim 1, wherein R¹ and R² groups are each independently hydrogen, OH, CH₃, CH₂CH₃, OCH₃, CH₂OH, CH₂OCH₃, CH₂NH₂, CH₂NHCH₃, NH₂, or CH₂NH₂, or R¹ and R², taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring.

- 12. The compound of claim 1, wherein R^3 and R^4 are each independently Z- R^7 wherein Z is an optionally substituted C_{0-4} alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R^7 is selected from halogen, CN, N(R')₂, NHCOR', or R', or wherein R^3 and R^4 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- 13. The compound of claim 1, wherein R³ and R⁴ are each independently hydrogen, CN, halogen, OH, SH, NH₂, CO₂H, COH, CONH₂, SO₂NH₂, NO₂, (CH₂)_nNRR⁷, wherein R and R⁷, taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, or R³ and R⁴, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and n is 0, 1, 2, 3, 4, or 5.
- 14. The compound of claim 1, wherein one of R^3 or R^4 is hydrogen, and the other of R^3 or R^4 is $(CH_2)_n halogen$, $(CH_2)_n CN$, $(CH_2)_n OR^7$, $(CH_2)_n NRR^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n C(O)NRR^7$, $(CH_2)_n SR^7$, wherein R^7 is hydrogen, $(CH_2)_m N(R^2)_n C(CH_2)_n C(C$
- 15. The compound of claim 14, wherein R³ is hydrogen.
- 16. The compound of claim 14, wherein R⁴ is hydrogen.

- 17. The compound of claim 1, wherein R^3 and R^4 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is optionally substituted with 0, 1, 2, 3, 4, or 5 occurrences of Y- R^8 .
- 18. The compound of claim 17, wherein each occurrence of Y-R⁸ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF₃, OMe, OEt, CN, SO₂Me, SO₂NH₂, NH₂, NHMe, N(Me)₂, SMe, SEt, OH, C(O)Me, NO₂, or CH₂OH.
- 19. The compound of claim 1, having one of formulas I-A-i, I-A-ii, I-B-i, I-B-ii, I-C-i, I-C-ii, I-D-i, or I-E-i:

I-B-i

I-B-ii



 R^2 R_1 R_2 R_1 R_2 R_1 R_2 R_3 R_4

I-C-i

I-C-ii

$$R^2$$
 R_1
 R_1
 R_2
 R_1
 R_2
 R_3
 R_4
 R_4
 R_4
 R_4
 R_5
 R_4
 R_5
 R_4
 R_5
 R_5
 R_6
 R_7
 R_8


I-D-i

I-E-i

wherein q is 0-5.

- 20. The compound of claim 19, wherein Ar¹ is:
 - (a) a phenyl, indanyl, or naphthyl ring;
- (b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
 - (c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.
- 21. The compound of claim 19, wherein Ar¹ is:
 - (a) a phenyl ring;
 - (b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
 - (c) a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.

22. The compound of claim 19, wherein Ar¹ is any one of **a-bb**:



wherein Q and R⁵ are as defined generally above and in subsets herein, and x is 0-5.

- 23. The compound of claim 19, wherein Ar¹ is phenyl, pyrimidinyl, or pyridyl.
- 24. The compound of claim 19, wherein Ar^1 is phenyl and is substituted with two (x = 2) or three (x = 3) occurrences of $Q-R^5$ and Ar^1 is one of the following structures:

$$QR^5$$
 QR^5
 QR^5
 QR^5
 QR^5
 QR^5

wherein each occurrence of QR⁵ is independently CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂PO(OR')₂, PO(OR')₂.

25. The compound of claim 19, wherein Ar¹ is optionally substituted phenyl and compounds have one of formulas II-A-i, II-A-ii, II-B-ii, II-B-ii, II-C-ii, II-C-ii, II-D-i, or II-E-i:

 $\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\$

$$\begin{array}{c|c} & & & \\ & & & \\$$

II-A-i

II-A-ii

HN R^2 R_1 R_1 R_2 R_3 R_1 R_2 R_3 R_4 R_5 R_5

$$R^2$$
 R_1
 R_1
 R_2
 R_1
 R_2
 R_1
 R_2
 R_3
 R_1
 R_2
 R_3

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

II-C-i

II-C-ii

$$R^2$$
 R_1
 R_1
 R_2
 R_1
 R_1
 R_2
 R_1
 R_2
 R_3
 R_4
 R_4
 R_4
 R_5
 R_4
 R_5
 R_6
 R_7
 R_8

II-D-i

II-E-i

where x and q are each independently 0-5.

- 26. The compound of claim 25, wherein each occurrence of Q is independently a bond or is an optionally substituted C_1 - C_4 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO₂, CONR, OCONR, NRCO, NRCO₂, NRSO₂, SO₂NR, O, S, or NR; and each occurrence of R⁵ is independently selected from R', halogen, NO₂, CN, OR', SR', N(R')₂, NR'C(O)R', NR'C(O)N(R')₂, NR'CO₂R', C(O)R', CO₂R', OC(O)R', C(O)N(R')₂, SOR', SO₂R', SO₂N(R')₂, NR'SO₂R', NR'SO₂N(R')₂, PO(OR')₂, C(O)C(O)R', or C(O)CH₂C(O)R', and x is 0, 1, 2, or 3.
- 27. The compound of claim 25, wherein each occurrence of Q-R⁵ is independently CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂, or two adjacent occurrences of Q-R⁵, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.
- 28. The compound of claim 25, wherein each occurrence of Q-R⁵ is independently fluoro, iodo, chloro, bromo, COCH₃, CO₂CH₃, C₁₋₄alkyl, NH₂, CH₂NH₂, NHMe, CH₂NHMe, N(Me)₂, CH₂N(Me)₂, N(Et)₂, CH₂N(Et)₂, NH(phenyl), CO(C₁₋₄alkyl), CH₂CO(C₁₋₄alkyl), NHCO(C₁₋₄alkyl), CH₂NHCO(C₁₋₄alkyl), CN, CH₂CN, OH, C₁₋₄alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF₃, SO₂NH₂, SO₂NHMe, optionally substituted

SO₂(phenyl), SO₂(C₁₋₄alkyl), CONH₂, CH₂PO(OR')₂, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

- 29. The compound of claim 25, wherein R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S.
- 30. The compound of claim 29, wherein R¹ and R² are each independently hydrogen, OH, CH₃, CH₂CH₃, OCH₃, CH₂OH, CH₂OCH₃, CH₂NH₂, CH₂NHCH₃, NH₂, or CH₂NH₂, or R¹ and R², taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring.
- 31. The compound of claim 25, wherein R^3 is $Z-R^7$, wherein Z is a bond or is an optionally substituted C_{0-4} alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R^7 is halogen, CN, N(R')₂, NHCOR', or R'.
- 32. The compound of claim 25, wherein R^3 is $(CH_2)_n$ halogen, $(CH_2)_n CN$, $(CH_2)_n OR^7$, $(CH_2)_n NRR^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n C(O)R^7$ $(CH_2)_n CH_3$, $(CH_2)_n C(O)NRR^7$, $(CH_2)_n SR^7$, wherein R^7 is $(CH_2)_m N(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.
- 33. The compound of claim 25, wherein R^4 is $Z-R^7$, wherein Z is a bond or is an optionally substituted C_{0-4} alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R^7 is selected from halogen, CN, N(R')₂, NHCOR', or R'.

- 34. The compound of claim 25, wherein R^4 is $(CH_2)_n$ halogen, $(CH_2)_n CN$, $(CH_2)_n CN^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n C(O)R^7$, $(CH_2)_n CH_3$, $(CH_2)_n C(O)NRR^7$, $(CH_2)_n SR^7$, wherein R^7 is $(CH_2)_m N(R^2)_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, R is 0 or 1, and R is 0 or 1.
- 35. The compound of claim 25, wherein q is 0, 1, or 2, and each occurrence of Y-R⁸ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF₃, OMe, OEt, CN, SO₂Me, SO₂NH₂, NH₂, NHMe, N(Me)₂, SMe, SEt, OH, C(O)Me, NO₂, or CH₂OH.
- 36. The compound of claim 25, wherein compounds have one of formulas II-A-i, II-B-i, or II-C-i, and the compound variables are defined as:
- a) x is 0, 1, 2, or 3, and Q-R⁵ is CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂, or Q-R⁵, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;
- b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and
- c) R^3 is $(CH_2)_n halogen$, $(CH_2)_n CN$, $(CH_2)_n OR^7$, $(CH_2)_n NRR^7$, $(CH_2)_n C(O)R^7$, wherein R^7 is $(CH_2)_m N(R^7)_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, R is 0 or 1, and R is 0 or 1.

- 37. The compound of claim 25, wherein compounds have one of formulas II-A-ii, II-B-ii, or II-C-ii, and one or more of the compound variables are defined as:
- a) x is 0, 1, 2, or 3, and Q-R⁵ is CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂, or Q-R⁵, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;
- b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and
- c) R^4 is $(CH_2)_n halogen$, $(CH_2)_n CN$, $(CH_2)_n OR^7$, $(CH_2)_n NRR^7$, $(CH_2)_n C(O)R^7$, wherein R^7 is $(CH_2)_m N(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.
- 38. The compound of claim 25, wherein compounds have formula **II-E-i**, and one or more of the compound variables are defined as:
- a) x is 0, 1, 2, or 3, and Q-R⁵ is CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂, or Q-R⁵, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;
- b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully

unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and

c) q is 0, 1, or 2, and each occurrence of Y-R⁸ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF₃, OMe, OEt, CN, SO_2Me , SO_2NH_2 , NH_2 , NHMe, $N(Me)_2$, SMe, SEt, OH, C(O)Me, NO_2 , or CH_2OH .

39. The compound of claim 1, selected from:


I-15

I-16 I-17 I-18 I-9 I-20 I-21 I-22 I-23 I-24 I-25 I-26 I-27 I-28 I-29 I-30 I-31 I-32 I-33 I-34 I-35 I-36 I-37 I-38 I-39 I-40 I-42 I-41 I-43 I-44 I-45

- 121 -

I-47

I-48





I-58 I-59 I-60 I-61 I-62 I-63 I-64 I-66 I-65

I-67 I-68 I-69 I-70 I-71 I-72

I-74

I-75





I-76

I-77

HN N S N

I-79


I-82

I-83

I-85 I-86 I-87 I-88 I-89 **I-90**

I-92

I-93




I-96

I-97

I-98


I-99



I-100

I-101

I-102



I-103

I-104

I-109

I-113

I-107

I-110

I-114


I-108


I-111


I-116 I-117 I-118 I-119 I-120 I-121

-ОН

I-122 I-123 I-124








I-126

I-127

I-128


I-129


I-130



I-131

I-132






I-147

I-148

I-149

I-150




I-151

I-152

I-154 I-155 I-156 I-157 I-158 I-159 Ю но

I-161

I-162



I-171

-NH₂ -NH₂ I-184 I-185 I-186 NH₂ I-187 I-188 I-189

I-191

I-192

I-196 I-197 I-198

I-199 I-200

I-201 I-202 I-203 HŅ ΗŅ I-204 I-205 **I-206** _OH ΗŅ

I-208

I-209

_OH I-210 I-211 I-212 I-213 I-214 I-215 I-216 I-217 I-218 I-219 I-220 I-221 I-222 I-223 I-224 ΗŅ I-225 I-226 I-227

I-237 I-238 I-239 HO' I-240 I-241 ΗŅ HN

I-243

I-244

I-245 I-247 I-246 I-248 I-249 I-250 ΗŃ ΗŃ ю I-252 I-251 I-253

I-255


I-256

S NH NH NH I-263

I-265 I-266 I-267 I-268

I-270

I-271



- 40. A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- 41. The composition of claim 40, wherein the compound is in an amount to detectably inhibit SYK, or ZAP-70 protein kinase activity.
- 42. The composition of claim 40, additionally comprising a therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders.

- 43. A method of inhibiting SYK or ZAP-70 kinase activity in:
 - (a) a patient; or
 - (b) a biological sample;

which method comprises administering to said patient, or contacting said biological sample with:

- a) a composition of claim 40; or
- b) a compound of claim 1.
- 44. A method of treating or lessening the severity of treatment or lessening the severity of an immunodeficiency disorder, inflammatory disease, allergic disease, autoimmune disease, proliferative disorder, immunologically-mediated disease, or respiratory disorder, comprising the step of administering to said patient:
 - a) a composition of claim 40; or
 - b) a compound of claim 1.
- 45. The method according to claim 44, comprising the additional step of administering to said patient an additional therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

- 46. The method according to claim 44, wherein the disease is an immune disorder.
- 47. The method according to claim 44, wherein the disease is asthma.